Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré Bioscience announced the publication of Phase 1 clinical trial results for its topical Sildenafil Cream in Menopause - The Journal of The Menopause Society. The study of 21 postmenopausal women found the cream was well-tolerated with minimal systemic exposure compared to oral dosing, supporting its use for female sexual arousal disorder.
Key figures
- Drug Name
- Sildenafil Cream
- Phase Of Trial
- Phase 1
- Dose levels mg
- [50,100,200]
- Mean age years
- 57
- Participants enrolled
- 21
- Participants completed
- 19
- Max plasma concentration pg ml
- 3810
- Oral comparison concentration pg ml
- 450000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.